Fundacja Pro-ZdroFoundation

Other human health activities not elsewhere classified

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2017-03-20
Registered address
ul. Jana Kasprowicza 6, 98-100 Łask, Poland
Electronic delivery address
AE:PL-76222-73835-TJRBW-30

Financials

Total Operating Costs
22.03k
+2,035.2% vs 2022

Revenue history (in k)

Filing timeliness

No financial statement for 2025 – the filing deadline has passed. 2 of 6 financial statements were filed late (the longest delay 91 days for 2021).

  • 2025not filed
  • 202414/07/2025
  • 202302/07/2024
  • 202210/08/2023
  • 202114/10/2022
  • 202012/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2024.

Results vs industry

Revenue
This companyUSD 21.92kMedianUSD 91.95kAverageUSD 1.38m
Net profit
This companyUSD -108.77MedianUSD 2.66kAverageUSD 145.95k
Operating costs
This companyUSD 22.03kMedianUSD 82.81kAverageUSD 1.19m
Assets
This companyUSD 945.10MedianUSD 39.40kAverageUSD 951.16k

Authorized Representatives

Beata Anna Miksa – President of the Management Board
Renata Lidia Cholerzyńska – Vice President of the Management Board
Ewa Wróbel – Management Board Member
Iwona Zdzisława Słobodzian – Management Board Member

Manner of representation

Declarations of will on behalf of the foundation, including in property matters, in the case of a one-person management board, are made by the President independently, and in the case of a multi-member management board, joint action by the Vice-President or one of the members of the management board is required.

Supervisory board

Artur Andrzej Miksa – Supervisory Board Member
Katarzyna Małgorzata Dronka – Supervisory Board Member

Beneficial owners

Person

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,043

FAQ

Last updated: 2026-03-28